Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
South Texas Oncology and Hematology, PA South Texas Oncology (2)
mi
from
San Antonio, TX
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
South Texas Oncology and Hematology, PA South Texas Oncology (2)
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
Stanford University Medical Center Stanford
mi
from
Stanford, CA
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
Stanford University Medical Center Stanford
mi
from
Stanford, CA
Click here to add this to my saved trials
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
University of California at Los Angeles UCLA SC
mi
from
Los Angeles, CA
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
University of California at Los Angeles UCLA SC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 2
mi
from
Madison, WI
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 2
mi
from
Madison, WI
Click here to add this to my saved trials
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
Vanderbilt University Medical Center Vanderbilt - Thompson Ln
mi
from
Nashville, TN
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
Vanderbilt University Medical Center Vanderbilt - Thompson Ln
mi
from
Nashville, TN
Click here to add this to my saved trials
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
Yale University School of Medicine Yale Univ
mi
from
New Haven, CT
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
Yale University School of Medicine Yale Univ
mi
from
New Haven, CT
Click here to add this to my saved trials
Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer
Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer
Status: Enrolling
Updated:  4/9/2014
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer
Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer
Status: Enrolling
Updated: 4/9/2014
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pilot Phase I HER-2 Pulsed-DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy
Pilot Phase I HER-2 Pulsed-DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy
Status: Enrolling
Updated:  4/9/2014
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Pilot Phase I HER-2 Pulsed-DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy
Pilot Phase I HER-2 Pulsed-DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy
Status: Enrolling
Updated: 4/9/2014
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Arizona Center for Cancer Care
mi
from
Glendale, AZ
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Arizona Center for Cancer Care
mi
from
Glendale, AZ
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Desert Springs Cancer Care
mi
from
Scottdale, AZ
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Desert Springs Cancer Care
mi
from
Scottdale, AZ
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Innovative Clinical Research Institute
mi
from
Burbank, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Innovative Clinical Research Institute
mi
from
Burbank, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
California Cancer Associates for Research and Excellence
mi
from
Fresno, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
California Cancer Associates for Research and Excellence
mi
from
Fresno, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Beaver Medical Group
mi
from
Highland, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Beaver Medical Group
mi
from
Highland, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
California Cancer Associates for Research and Excellence
mi
from
Los Angeles, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
California Cancer Associates for Research and Excellence
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
North County Oncology
mi
from
Oceanside, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
North County Oncology
mi
from
Oceanside, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Hematology Oncology Medical Group
mi
from
Orange, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Hematology Oncology Medical Group
mi
from
Orange, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Comprehensive Cancer Center At Desert Regional Medical Center
mi
from
Palm Springs, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Comprehensive Cancer Center At Desert Regional Medical Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Sarcoma Oncology
mi
from
Santa Monica, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Sarcoma Oncology
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
University Cancer Institute, LLC
mi
from
Boynton Beach, FL
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
University Cancer Institute, LLC
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Northeast Georgia Cancer Care
mi
from
Athens, GA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Northeast Georgia Cancer Care
mi
from
Athens, GA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Edward H. Kaplan, M.D. & Associates
mi
from
Skokie, IL
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Edward H. Kaplan, M.D. & Associates
mi
from
Skokie, IL
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Kentucky Cancer Clinic
mi
from
Hazard, KY
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Kentucky Cancer Clinic
mi
from
Hazard, KY
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Saint Louis University
mi
from
St. Louis, MO
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Saint Louis University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
New York Oncology Hematology PC
mi
from
Albany, NY
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
North Shore Hematology/Oncology Associates
mi
from
Setauket, NY
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
North Shore Hematology/Oncology Associates
mi
from
Setauket, NY
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
The Mark H. Zangmeister Center
mi
from
Columbus, OH
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
The Mark H. Zangmeister Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Good Samaritan Hospital, Corvallis
mi
from
Corvallis, OR
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Good Samaritan Hospital, Corvallis
mi
from
Corvallis, OR
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Banner Health
mi
from
Phoenix, AZ
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Banner Health
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Sutter Institute
mi
from
Sacramento, CA
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Sutter Institute
mi
from
Sacramento, CA
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Scripps
mi
from
San Diego, CA
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Scripps
mi
from
San Diego, CA
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Sansum Clinic
mi
from
Santa Barbara, CA
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Sansum Clinic
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Lahey Clinic
mi
from
Peabody, MA
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Lahey Clinic
mi
from
Peabody, MA
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Henry Ford Hospital
mi
from
Detroit, MI
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Rhode Island Hospital
mi
from
Providence, RI
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Avera Research Institute
mi
from
Sioux Falls, SD
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Avera Research Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Mastectomy Skin Flap Viability
The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Intraoperative Mastectomy Skin Flap Viability During Breast Reconstruction
Status: Enrolling
Updated:  5/12/2014
Stony Brook University
mi
from
Stony Brook, NY
The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Mastectomy Skin Flap Viability
The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Intraoperative Mastectomy Skin Flap Viability During Breast Reconstruction
Status: Enrolling
Updated: 5/12/2014
Stony Brook University
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Free Fatty Acid Metabolite Biomarkers for Cancer
Status: Enrolling
Updated:  5/14/2014
Cleveland Clinic
mi
from
Cleveland, OH
Free Fatty Acid Metabolite Biomarkers for Cancer
Status: Enrolling
Updated: 5/14/2014
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status: Enrolling
Updated:  5/22/2014
University of Kansas Medical Center
mi
from
Kansas City, KA
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status: Enrolling
Updated: 5/22/2014
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status: Enrolling
Updated:  5/22/2014
Cotton-O-Neil Cancer Center (Stormont Vail Health Care)
mi
from
Topeka, KA
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status: Enrolling
Updated: 5/22/2014
Cotton-O-Neil Cancer Center (Stormont Vail Health Care)
mi
from
Topeka, KA
Click here to add this to my saved trials
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status: Enrolling
Updated:  5/22/2014
Truman Medical Center
mi
from
Kansas City, MO
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status: Enrolling
Updated: 5/22/2014
Truman Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies
Status: Enrolling
Updated:  6/2/2014
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies
Status: Enrolling
Updated: 6/2/2014
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies
Status: Enrolling
Updated:  6/2/2014
Windber Medical Center
mi
from
Windber, PA
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies
Status: Enrolling
Updated: 6/2/2014
Windber Medical Center
mi
from
Windber, PA
Click here to add this to my saved trials
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients
Status: Enrolling
Updated:  6/2/2014
Walter Reed Army Medical Center
mi
from
Washington,
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients
Status: Enrolling
Updated: 6/2/2014
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients
Status: Enrolling
Updated:  6/2/2014
Windber Medical Center
mi
from
Windber, PA
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients
Status: Enrolling
Updated: 6/2/2014
Windber Medical Center
mi
from
Windber, PA
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Scottsdale Healthcare
mi
from
Scottsdale, AZ
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Integrative Approaches for Cancer Survivorship
A Whole Systems Approach to the Study of Ayurveda for Cancer Survivorship, Project II
Status: Enrolling
Updated:  7/10/2014
University of California, San Francisco, Osher Center for Integrative Medicine
mi
from
San Francisco, CA
Integrative Approaches for Cancer Survivorship
A Whole Systems Approach to the Study of Ayurveda for Cancer Survivorship, Project II
Status: Enrolling
Updated: 7/10/2014
University of California, San Francisco, Osher Center for Integrative Medicine
mi
from
San Francisco, CA
Click here to add this to my saved trials